Streptokinase: About of a thrombolytic patented in Cuba;Estreptoquinasa: A propósito de un agente trombolítico patentado en Cuba

Biotecnologia Aplicada

Volumn 22, Issue 3, 2005, Pages 182-198

  Hernández, Luciano ^a   Marrero, María A ^b  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Centro Nacional Coordinador de Ensayos Clinicos   (Cuba)

Author keywords

Streptokinase; Thrombolytic agents; Tissue type plasminogen activator; Urokinase

Indexed keywords

EID: 76749086116     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Collen D, Stump DC, Gold HK. Thrombolytic therapy. Annu Rev Med 1988; 39:405-23.
2. Collen D. Coronary Thrombolysis: streptokinase or recombinant tissue plasminogen activator? Ann Intern Med 1990;112:529-38.
3. Francis CW, Marder VJ. Fibrinolytic therapy for venous thrombosis. Prog Cardiovasc Dis 1991;34(3):193-204.
4. Sherry S, Marder VJ. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction. Ann Intern Med 1991;114:417-23.
5. Early thrombolysis for the treatment of acute myocardial infarction: a systemic review and economic evaluation. Heath Technology Assessment 2003;7:15.
6. Paoletti R, Sherry S, editors. Proceedings of the serono symposia. Thrombosis and Urokinase, vol. 9. London: Academic Publisher, 1977. p. 257.
7. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996;47:315-31.
8. Castellino FJ. Recent advances in the chemistry of the fibrinolytic system. Chem Rev 1981;81:431-46.
9. Castellino FJ. Biochemistry of human-plasminogen. Semin Thromb Hemost 1984;10:18-23.
10. Francis CW, Marder VJ. Fibrinolytic therapy for venous thrombosis. Prog Cardiovasc Dis 1991;34(3):193-204.
11. Bajaj AP, Castellino FJ. Activation of human plasminogen by equimolar levels of streptokinase. J Biol Chem 1977; 252: 492-8.
12. Camiolo SM, Thorsen S, Astrup T. Fibrinógenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971; 138:277-80.
13. Barlow GH. Urinary and kidney cell plasminogen activator (urokinase). Methods Enzymol 1976;45:239-44.
14. Tillett WS, Garner RL. Fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485-502.
15. Collen D, Bounameaux H, De Cook F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986;73:511-7.
16. Walker JE, Ogstron D. The inhibition of tissue activator and urokinase by human plasma. Thromb Haemost 1982;47:265.
17. Schreider P, Bachmann F, Sauser D. Urokinase: a short review of its properties and of its metabolism. In: D'Angelo A, Urokinase: basic and clinical aspects. London: Academic Press 1982:1-15.
18. Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme inhibitor complex. Proc Nat Acad Sci (USA) 1983;80:6804-8.
19. Dodd I, Nunn B, Robinson JH. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. Thromb Haemost 1988;59:523-8.
20. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) Trial, phase I: A comparison betwen intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-54.
21. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. For Adis. Drug 44: 293-325;1992.
22. Bugelski PJ Fong KL, et al. Uptake of human recombinant tissue type plasminogen activator by rat hepatocytes in vivo: an electron microscope autoradiographic study. Tromb Res 1989; 53:287-303.
23. Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded tPA deletion variant BM 06.022. Protein Eng 1992;66:569-74.
24. Martin U, Bader R, Böhm E, et al. BM 06.022: a novel recombinant plasminogen activator. Cardiovasc Drug Rev 1993;11:299-311.
25. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase duoble-bolus administration with strep - tokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346:329-36.
26. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-32.
27. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM et al. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase and front-loaded, «accelerated» alteplase in patients with acute myocardial infarction. Circulation 1996;94(5):891-8.
28. GUSTO III Investigators. A comparison of Reteplase with Alteplase for acute myocardial infarction. N Engl J Med 1997;337(16):1118-23.
29. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-14.
30. Keyt BA, Paoni NF, Refino CJ et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci (USA) 1994;91:3670-4.
31. Modi NB, Fox NL, Clow F-W, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000;40:508-15.
32. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Lancet 1999 Aug 28;354(9180):716-22.
33. Inoue T, Yaguchi I, Takayanagi K, Hayashi T, Morooka S, Eguchi Y. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the Combining Monteplase with Angioplasty (COMA) trial. Am Heart J 2002;144(4):E5.
34. Suzuki Y, Kano T, Katayama Y, Tejima E, Harada T. Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life. Neurological Research July 2003;25(5):477-80(4).
35. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21(24):2005-13.
36. Malke H, Ferretti JJ. Streptokinase: cloning, expression and excretion by Escherichia coli. Proc Natl Acad Sci (USA) 1984;81:3557-61.
37. De Renzo EC, Siiteri PK, Hutchings BL, Bell PH. Preparation and certain properties of highly purified streptokinase. J Biol Chem 1967;242:533-42.
38. Taylor FB, Botts J. Purification and characterization of streptokinase with studies of streptokinase activation of plasminogen. Biochemistry 1968;7:232-42.
39. Brockway WJ, Castellino FJ. A characterization of native streptokinase and altered streptokinase isolated from a human plasminogen activator complex. Biochemistry 1974;13:2063-70.
40. Huang TT, Malke H, Ferretti JJ. Heterogeneity of the streptokinase gene in group A Streptococci. Infect Immun 1989;57: 502-6.
41. Malke H. Polymorphism of the streptokinase gene-implications for the pathogenesis of poststreptococcal glomerulonephritis. Zentralbl Bakteriol 1993; 278:246-57.
42. McCoy HE, Broder CC, Lottenberg R. Streptokinases produced by pathogenic group C Streptococci demostrate species-specific plasminogen activation. J Infect Dis 1991;164:515-21.
43. Welfle K, Pfeil W, Misselwitz R, Welfle H, Gerlach D. Conformational properties of streptokinase-differential scanning calorimetric investigations. Int J Biol Macromol 1992;14:19-22.
44. Nihalani D, Kumar R, Rajagopal K, Sahni G. Role of the amino-terminal region of streptokinase in the generation of a fully functional plasminogen activator complex probed with synthetic peptides. Protein Sci 1998;7:637-48.
45. Kim IC, Kim JS, Lee SH, Byun SM. C-terminal peptide of streptokinase, Met369-Pro373, is important in plasminogen activation. Biotechnol Mol Biol Int 1996;40:939-45.
46. Kim DM, Lee SJ, Yoon SK, Byun SM. Specificity role of the streptokinase C-terminal domain in plasminogen activation. Biochem Biophys Res Commun 2002;290:585-8.
47. Zhai P, Wakeham N, Loy JA, Zhang XC. Functional roles of streptokinase C-terminal flexible peptide in active site formation and substrate recognition in plasminogen activation. Biochemistry 2003;42:114-20.
48. Kim DM, Lee SJ, Kim IC, Kim ST, Byun SM. Asp4-His48 region of streptokinase is important in binding to a substrate plasminogen. Thromb Res 2000;99:93-8.
49. Wakeham N, Terzyan S, Zhai PZ, Loy JA, Tang J, Zhang XC. Effects of deletion of streptokinase residues 48-59 on plasminogen activation. Protein Eng 2002; 15:753-61.
50. Wu DH, Shi GY, Chuang WJ, Hsu JM, Young KC, Chang CW et al. Coiled coil region of streptokinase gammadomain is essential for plasminogen activation. J Biol Chem 2001;276:15025-33.
51. Robinson BR, Liu L, Houng AK, Sazanova IY, Reed GL. The streptokinase beta domain plays a critical role in activator complex formation and substrate docking. Circulation 2000;102:490.
52. Boxrud PD, Bock PE. Streptokinase binds preferentially to the extended conformation of plasminogen through lysine binding site and catalytic domain interactions. Biochemistry (USA) 2000; 39:13974-81.
53. Boxrud PD, Verhamme IMA, Fay WP, Bock PE. Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabilizes the active zymogen conformation. J Biol Chem 2001;276: 26084-9.
54. Shi GY, Chang BI, Chen SM, Wu DH, Wu HL. Function of streptokinase fragments in plasminogen activation. Biochem J 1994;304:235-41.
55. Young KC, Shi GY, Chang YF, Chang BI, Chang LC, Lai MD et al. Interaction of streptokinase and plasminogen -studied with truncated streptokinase peptides. J Biol Chem 1995;270:29601-6.
56. Brockway WJ, Castellino FJ. A characterization of native streptokinase and altered streptokinase isolated from a human plasminogen activator complex. Biochemistry 1974;13:2063-70.
57. Markus G, Evers JL, Hobika GH. Activator activities of the transient forms of the human plasminogen streptokinase complex during its proteolytic conversion to the stable activator complex. J Biol Chem 1976; 251:6495-504.
58. Siefring GE, Castellino FJ. Interaction of streptokinase with plasminogen: isolation and characterization of a streptokinase degradation product. J Biol Chem 1976;251:3913-20.
59. Rodríguez P, Fuentes D, Muñoz E, Rivero D, Orta D, Alburquerque S et al. The streptokinase domain responsible for plasminogen binding. Fibrinolysis 1994; 8:276-85.
60. Reed GL, Lin LF, Parhami-Seren B, Kussie P. Identification of a plasminogen binding region in streptokinase that is necessary of the creation a functional streptokinase-plasminogen activator complex. Biochemistry 1995;34:10266-71.
61. Chibber BAK, Castellino FJ. Regulation of the streptokinase-mediated activation of human plasminogen by fibrinogen and chloride ions. J Biol Chem 1986;261:5289-95.
62. Marder VJ, Sherry S. Thombolytic therapy. Current status. N Engl J Med, 1988;318:1512-20,1585-95.
63. Wu XC, Ye RQ, Duan YJ, Wong SL. Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. Appl Environ Microbiol 1998;64:824-9.
64. ISIS-2(Second International Study of Infarct Survival) Colaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17.187 cases of suspected acute myocardial infarction; ISIS-2. Lancet 1988;ii:349-60.
65. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 1981;290:505-8.
66. Monk JP, Heal RC. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Drugs 1987;34:25-49.
67. Fay WP, Bokka LV. Functional analysis of the amino- and carboxyl-termini of streptokinase. Thromb Hemost 1998; 79:985-91.
68. Medved LV, Solovjov DA, Ingham KC. Domain structure, stability and interactions in streptokinase. Eur J Biochem 1996; 239:333-9.
69. Lee SH, Kim IC, Bae KH, Byun SM. Enhanced production and secretion of streptokinase into extracellular medium in Escherichia coli by removal of 13 Nterminal amino acids. Biotechnol Lett 1997;19:151-4.
70. Wang SG, Reed GL, Hedstrom L. The deletion of Ile1 changes the mechanism of streptokinase. FASEB J 1999;13:A1535.
71. Torrens I, Ojalvo AG, Seralena A, de la Fuente J. Study of antigenic regions of streptokinase. Thromb Hemost 1999; 2288:Suppl S.
72. Torrens I, Ojalvo AG, Seralena A, Hayes O, de la Fuente J. A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunol Lett 1999b;70:213-8.
73. Robinson BR, Liu L, Houng AK, Sazanova IY, Reed GL. The streptokinase beta domain plays a critical role in activator complex formation and substrate docking. Circulation 2000;102:490.
74. Wakeham N, Terzyan S, Zhai PZ, Loy JA, Tang J, Zhang XC. Effects of deletion of streptokinase residues 48-59 on plasminogen activation. Protein Eng 2002;15:753-61.
75. Sundram V, Nanda JS, Rajagopal K, Dhar J, Chaudhary A, Sahni G. Domain truncation studies reveal that the strepto-kinase-plasmin activator complex utilizes long range protein-protein interactions with macromolecular substrate to maximize catalytic turnover. J Biol Chem 2003; 278: 30569-77.
76. Shi GY, Chang BI, Su SW, Young KC, Wu DH, Chang LC et al. Preparation of a novel streptokinase mutant with improved stability. Thromb Hemost 1998;79:992-7.
77. Pratap J, Rajamohan G, Dikshit KL. Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosyla-tion. Appl Microbiol Biotechnol 2000;53: 469-75.
78. Koide A, Suzuki S, Kobayashi S. Preparation of polyethylene glycol-modified streptokinase with disappearan-ce of binding ability towards antiserum and retention of activity. FEBS Lett 1982; 143:73-6
79. Rajagopalan S, Gonias SL, Pizzo SV. A non-antigenic covalent streptokinase polyethylene glycol complex with plasmi-nogen activator function. J Clin Invest 1985;75:413-9.
80. Reed GL, Kussie P, Parhamiseren B. A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. J Immunol 1993;150:4407-15.
81. ParhamiSeren B, Keel T, Reed GL. Structural characterization of immunodominant regions of streptokinase recognized by murine monoclonal antibodies. Hybridoma 1996;15:169-76.
82. ParhamiSeren B, Keel T, Reed GL. Sequences of antigenic epitopes of streptokinase identified via random peptide libraries displayed on phage. J Mol Biol 1997;271:333-41.
83. Coffey JA, Jennings KR, Dalton H. New antigenic regions of streptokinase are identified by affinity-directed mass spectrometry. Eur J Biochem 2001; 268:5215-21.
84. Ojalvo AG, Pozo L, Labarta V, Torrens I. Prevalence of circulating antibodies against a streptokinase C-terminal peptide in normal blood donors. Biochem Biophys Res Commun 1999a;263:454-9.
85. Lancefield RC. A serological differentiation of human and other groups of hemolytic Streptococci. J Exp Med 1933; 57:571-95.
86. Christensen LR. Streptococcal fibrinolysis: a proteolytic reaction due to serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol 1945;28:363-83.
87. Feldman LJ. Streptokinase manu-facture. In German. German patent DE 2354019 (1974).
88. Malke H, Roe B, Ferretti J. Nucleotide sequence of the streptokinase gene from Streptococcus equisimilis H46A. Gene 1985; 34:357-62.
89. Hagenson MJ, Holden KA, Parker KA, Wood PJ, Cruze JA, Fuke M et al. Expression of streptokinase in Pichia pastoris yeast. Enzyme Microb Technol 1989;11:650-6.
90. Wong SL, Ye RQ, Nathoo S. Engineering and production of streptokinase in Bacillus subtilis expresion-secretion system. Appl Environ Microbiol 1994;60:517-23.
91. Gase K, Ellinger T, Malke H. Complex transcriptional control of the streptokinase gene of Streptococcus equisimilis H46A. Mol Gen Genet 1995;247:749-58.
92. Grafe S, Ellinger T, Malke H. Structural dissection and functional analysis of the complex promoter of the streptokinase gene from Streptococcus equisimilis H46A. Med Microbiol Immun 1996;185:11-7.
93. Estrada MP, Hernández L, Pérez A, Rodríguez P, Serrano R, Rubiera R et al. High-level expression of streptokinase in Escherichia coli. Biotechnology 1992;10:1138-42.
94. Ko JH, Park DK, Kim IC, Lee SH, Byun SM. High-level expression and secretion of streptokinase in Escherichia coli. Biotechnol Lett 1995;17:1019-24.
95. Lee Sh, Kim IC, Bae KH, Byun SM. Enhanced production and secretion of streptokinase into extracellular medium in Escherichia coli by removal of 13 N-terminal amino acids. Biotechnol Lett 1997;19:151-4.
96. Yazdani SS, Mukherjee KJ. Overexpression of streptokinase using a fed-batch strategy. Biotechnol Lett 1998;20:923-7.
97. Zhang XW, Sun T, Huang XN, Liu X, Gu DX, Tang ZQ. Recombinant streptokinase production by fed-batch cultivation of Escherichia coli. Enzyme Microb Technol 1999;24:647-50.
98. Yazdani SS, Mukherjee KJ. Continuous culture studies on the stability and expression of recombinant streptokinase in Escherichia coli. Bioprocess Biosyst Eng 2002;24:341-6.
99. Muller J, Malke H. Duplication of the streptokinase gene in the chromosome of Streptococcus equisimilis H46A. FEMS Microbiol Lett 1990;72:75-8.
100. Estrada MP, Felipe AP, Chaple RR, Serrano R, Hernández L, Rodríguez P, et al., inventors; Centro de Ingeniería Genética y Biotecnología, Cuba, assignee. Method for the isolation of a gene which codes for streptokinase, nucleotide sequence obtained, recombinant DNA and transformed microorganisms. US patent 5,296,366. 1994 Mar 22.
101. Bernheimer AW, Gillman W, Hottle GA, Pappenheimer AM. An improved medium for the cultivation of hemolytic streptococcus. J Bacteriol 1942;43:495-8.
102. Ozegowski JH, Gerlach D, Kohler W. Influence of physical parameters on the production of streptococcal extracellular proteins in cultures with stabilized pH: 2. Temperature dependence of extracellular protein production. Zentralbl Bakteriol, Microbiol Hyg 1983;254:361-9.
103. Remmert LMF, Cohen PP. Partial purification and properties of a proteolytic enzyme of human serum. J Biol Chem 1949;181: 431-48.
104. Mullertz S. Formation and properties of the activator of plasminogen and of human and bovine plasmin. Biochem J 1955;61:424-34.
105. Derechin M. Hydrolysis of some casein fractions with lasmin. Biochem J 1962; 82:42-7.
106. Wallen P. Purification of human plasminogen: I. The purification of a partially purified human plasminogen with a low spontaneous proteolytic activity. Ark Kemi 1962;19:451-68.
107. Tomar RH. Streptokinase: preparation, comparison with streptococcal proteinase, and behavior as a trypsin substrate. Proc Soc Exp Biol Med 1968;127:239-44.
108. Saksela O. Radial caseinolysis in agarose: a simple method for detection of plasminogen activators in the presence of inhibitory substances and serum. Anal Biochem 1981;111:276-82.
109. Permin PM. Properties of the fibrinokinasefibrinolysin system. Nature 1947; 160:571-2.
110. Marsh NA, Gaffney PJ. The rapid fibrin platea method for plasminogen activator assay. Thromb Hemost 1977;38:545-51.
111. Westlund LE, Andersson LO. Variables influencing the clot lysis assay of streptokinase. Thromb Res 1991;64:713-21.
112. Mullertz S. Effect of carboxylic and amino acids on fibrinolysis produced by plasmin, plasminogen activator, and proteinases. Proc Soc Exp Biol Med 1954;85:326-9.
113. Troll W, Sherry S, Wachman J. The action of plasmin on synthetic substrates. J Biol Chem 1954;208:85-93.
114. Kline DL, Fishman JB. A simplified procedure for the isolation of purified human plasmin. Proc Intern Symp, Anticoagulants Fibrinolysins, Toronto;1961. p. 360-4.
115. Kline DL, Fishman JB. Improved procedure for the isolation of human plasminogen. J Biol Chem 1961;236:3232-4.
116. Sherry S, Alkjaersig N, Fletcher AP. Assay of urokinase preparations with the synthetic substrate acetyl-L-lysine methyl ester. J Lab Clin Med 1964;64:145-53.
117. Kulisek ES, Holm SE, Johnston KH. A chromogenic assay for the detection of plasmin generated by plasminogen activator immobilized on nitrocellulose using a paranitroanilide synthetic peptide substrate. Med Anal Biochem 1989;177:78-84.
118. Hernández L, Rodríguez P, Castro A, Serrano R, Rodríguez MP, Rubiera R. Determinación de actividad Sk utilizando un ensayo cuantitativo. Biotenología Aplica 1990;7(2): 153-60.
119. Taylor FB, Botts J. Purification and characterization of streptokinase with studies of streptokinase activation of plasminogen. Biochemistry 1968;7:232-42.
120. Einarsson M, Skoog B, Forsberg B, Einarsson R. Characterization of highly purified native streptokinase and altered streptokinase after alkaline treatment. Biochim Biophys Acta 1979;568:19-29.
121. Pérez N, Urrutia E, Camino J, Orta DR, Torres Y, Martínez Y, et al. Hydrophobic interaction chromatography applied to purification of recombinant streptokinase. Minerva Biotecnologica 1998;10:174-7.
122. Tomar RH. Streptokinase: preparation, comparison with streptococcal proteinase, and behavior as a trypsin substrate. Proc Soc Exp Biol Med 1968;127:239-44.
123. Castellino FJ, Sodetz JM, Brockway WJ, Siefring GE. Streptokinase. Methods Enzymol 1976;45:244-57.
124. Andreas EM. Affinity chromatographic purification of streptokinase with monoclonal antibodies. Allerg Immunol (Leipzig) 1990; 36:277-85.
125. Rodríguez P, Hernández L, Muñoz E, Castro A, Fuente JDL, Herrera L. Purification of streptokinase by affinity chromatography on inmovilized acylated human plasminogen. BioTechniques 1992;12:424.
126. Liu L, Houng A, Tsai J, Chowdhry S, Sazonova I, Reed GL. The fibronectin motif in the NH2-terminus of streptokinase plays a critical role in fibrin-independent plasminogen activation. Circulation 1999; 100(Suppl S):1.
127. The TERIMA Group Investigators. Multicenter, Randomized, Comparative Study of Recombinant vs Natural Streptokinases in Acute Myocardial Infarct (TERIMA). Thromb Haemost 1999;82:1605-9.
128. The TERIMA Group Investigators. TERIMA-2: National Extension of Thrombolytic Treatment with Recombinant Streptokinase in Acute Myocardial Infarct in Cuba. Thrombosis and Haemostasis 2000;84:949-54.
129. Mainet D, del Rosario M, Toruncha A, Prats P, Valenzuela C, López Saura P. Similar more than 6 months persisted, antibody and neutralizing with acute myocardial infarction treated with recombinant or natural streptokinase. Fibrinoilysis and Proteolysis 1998;12(5):301-9.